Last reviewed · How we verify
Furosemide plus Chlorothiazide
This combination of two loop and thiazide diuretics works by inhibiting sodium and chloride reabsorption in the kidney to increase urine output and reduce fluid overload.
This combination of two loop and thiazide diuretics works by inhibiting sodium and chloride reabsorption in the kidney to increase urine output and reduce fluid overload. Used for Edema and fluid overload in heart failure, renal disease, or hepatic cirrhosis, Resistant hypertension.
At a glance
| Generic name | Furosemide plus Chlorothiazide |
|---|---|
| Also known as | Lasix plus Diuril |
| Sponsor | Ochsner Health System |
| Drug class | Loop diuretic + thiazide diuretic combination |
| Target | Na-K-2Cl cotransporter (NKCC2) and Na-Cl cotransporter (NCC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Furosemide is a loop diuretic that blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, while chlorothiazide is a thiazide diuretic that inhibits the Na-Cl cotransporter in the distal convoluted tubule. Together, they provide synergistic diuretic and natriuretic effects, reducing blood volume and intracellular/extracellular fluid accumulation. This combination is used in resistant hypertension or severe edema where monotherapy is insufficient.
Approved indications
- Edema and fluid overload in heart failure, renal disease, or hepatic cirrhosis
- Resistant hypertension
Common side effects
- Hypokalemia
- Hyponatremia
- Hyperuricemia
- Ototoxicity (with high-dose furosemide)
- Hyperglycemia
- Dehydration
- Hypotension
Key clinical trials
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Protocol of Diuretics Use in Congestive Therapy in Heart Failure (PHASE4)
- Diuretics and Volume Overload in Early CKD (PHASE4)
- Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure (PHASE1)
- EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU) (NA)
- A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients (NA)
- Combination Diuretic Therapy for Acute Decompensated Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Furosemide plus Chlorothiazide CI brief — competitive landscape report
- Furosemide plus Chlorothiazide updates RSS · CI watch RSS
- Ochsner Health System portfolio CI